Podcasts about AbbVie

On this re-release episode of the Live Greatly 2 Minutes of Motivation podcast, Kristel Bauer shares 3  tips to help you receive feedback more effectively so you can grow personally and professionally. Learning how to accept constructive feedback without becoming defensive can strengthen your leadership skills, improve communication, and support long-term career success.  If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

Chalene Johnson breaks down the Instagram AI feature that had the internet in a panic last week, why deepfake scammers are now stealing real videos and subtly altering someone's voice and appearance to make fake endorsements look real, and what to watch for so you don't get fooled. She also shares a new survey showing that a large percentage of perimenopausal and menopausal women have no idea what stage of reproduction they're in, and explains why she's been getting stronger and leaner using a hormone marker called sex hormone binding globulin, or SHBG, something most doctors won't test unless you specifically request it. She recommends Midi Health for anyone who wants a full hormone panel done right. Chalene gives a quick update on the Blake Lively and Justin Baldoni legal saga, including the ongoing dispute over $8 million in legal fees, then moves into the difference between Botox, Juvederm, and Sculptra, her own experience with Sculptra after her facelift, and a new lawsuit against Juvederm maker AbbVie. She closes with a passionate defense of Madonna following her World Cup halftime performance, walking through Madonna's decades of reinvention, her physical training history, and why Chalene believes the ageism criticism aimed at her is completely out of line. Topics discussed: Instagram, AI deepfakes, perimenopause, menopause, sex hormone binding globulin, Midi Health, Blake Lively, Justin Baldoni, AB 933, Botox, Juvederm, AbbVie, Sculptra, Beauty Broker, Madonna, World Cup Go Beyond The Podcast Join Chalene on her private podcast

How can you strengthen your attention and perform at your best under pressure? In this episode of 2 Minutes of Motivation, Kristel Bauer shares three simple, science-backed strategies to help you improve your focus when it matters most. Whether you're preparing for a presentation, leading a meeting, or navigating a high-pressure moment, these actionable insights can help you stay focused on what matters most. Key Takeaways: How to recognize what's pulling your attention away Simple ways to redirect your focus in high-pressure moments Healthy habits that can strengthen your attention and resilience over time If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

Imagine a dark warehouse. Racks and racks of devices with wires, tubes, and electronics sticking out. The next AI data center? No. This is Lila Sciences‘ dream for the future of science. A dark warehouse full of AI-guided robotics and lab equipment, cranking out new experiments 24/7, building toward a scientific superintelligence.Their automated lab is almost hypnotizing to watch. They have floating plates zipping around on Wall-E-esque tracks, used vision-language models to control Windows 95 boxes, and created the world's largest collection of voided warranties. In the process they've built a massive library of scientific reasoning tokens. Over 10 trillion of them, all experimentally validated.No warranties were voided in the making of this videoTo say Lila is ambitious is an understatement. Their goal is a scientific superintelligence wired directly into the wet lab. They are all in on the bitter lesson, and the thesis follows from it: a lab is an infinite token generator. Produce data at scale, and the synergies give you a general reasoner that can tackle any scientific problem. They are committing hard. Biology, chemistry, drug discovery, and materials science, all at the same time. Time will tell if it works, but it is an exciting hypothesis.In our latest episode we sat down with Lila's very own Andy Beam (CTO) and Rafa Gómez-Bombarelli (CSO, physical sciences) and went on a journey through the possibilities of AI-run science, almost as wide-ranging as Lila's goals.Did we mention they do both materials science and biology? In the same AI science factory? Same time, same lab, same AI. Finally a guest who can settle a long-running debate we've had amongst ourselves: is biology or materials science harder?Watch to find out!We discuss:* The internet is spent, science is next. Why Lila thinks the scientific method is the last untapped internet-scale dataset, and why they treat RL as a data generation mechanism with nature as the verifier.* The lab as a data center. Instruments as nodes on a graph, a magnetically levitating “PCI bus” transport layer between them, orchestration as a slurm queue. Andy is not short on analogies.* Why Lila insists it is not an automation company. They optimize for flexibility and generalizability over raw throughput, which means humans stay below the API line wherever automating does not pay.* Your experiment has a runtime. We put Escalante Bio's question to Andy: if science is the token generator, what is the runtime of your data collection? His answer, in short, is that you cannot make the ribosome go faster. Why Lila bets on fast round-over-round iteration rather than big noisy multiplexed screens, and how Rafa's team rebuilt a gas sorption measurement to run roughly 2,500x faster.* What is actually in 10 trillion scientific tokens. Not sequences. Experimentally verified reasoning traces, a kind of data that Andy argues exists on the internet in quantities that round to zero.* Breadth as a path to depth. Small molecule chemistry priors transferring to metal organic frameworks for carbon capture, and the claim that the general model beats domain-specific models sample for sample.* If you have the data, what do you need the model for? Sri Kosuri's koan about the ML-for-drug-discovery business model, and Andy's answer: the coding model got better because it also read Shakespeare and carnitas recipes.* The serendipity they want to automate. Emily Whitehead survived the first pediatric CAR-T cure only because the doctor treating her happened to know, from pediatric arthritis, which antibody would blunt her IL-6 response. Roll that dice again and you probably lose her. Breadth is how you stop depending on luck.* Move 37 for catalysts. Model suggestions for platinum-group-free electrocatalysts that went from boring, to what a 40-paper expert called stupid, to the best performers they have made.* Six months to in vivo CAR-T data in non-human primates, and the zero-FTE virtual startup commercial model that fell out of it. For context on why that number is startling, AbbVie paid $2.1B for Capstan on the strength of preclinical in vivo CAR-T data.* You cannot have scientific superintelligence if you are just a good test taker. Ken Stanley, who wrote Why Greatness Cannot Be Planned, runs open-endedness at Lila. RL at scale gives you a ruthlessly Vulcan problem solver. Machine creativity is a different thing, and it is the part nobody has solved.* The chain of thought is an unreliable narrator. The model reasons in latent space and only emits tokens. Sometimes it skips the experiment entirely and is still right. So how much do you trust the reasoning versus the verifier?* Reward hacking when the rollout is physical. Chains of thought that collapse into repetition, and a model that got annoyed and swore at the scientist who kept asking it to redo a plate map. What happens when a pathological loop has a wet lab inside it?* The bittersweet lesson. Rafa's inversion of the bitter lesson: in AI, scaling is a roadmap. In materials, scaling is a filter, because only the things that scale end up mattering.* Not your typical Flagship company. Why a famously single-asset biotech incubator spun out a platform bet, and Andy's line that if Lila called itself a biopharma it would have a top-three GPU cluster.* Bottlenecks they would remove by fiat. Sim-to-real for physics-based simulation, and the fact that RL training runs at roughly 5% mean FLOP utilization.Watch on YouTube: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.latent.space/subscribe

Alissa Coram and Ken Shreve walk through Thursday's market action with key stocks to watch in Stock Market Today. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über eine neue Tonlage bei VW, die Folgen der Gesundheitsreform und was sonst noch wichtig wird in dieser Woche. Außerdem geht es um EasyJet, Apollo Global, IAG, Air France-KLM, Brink's, NCR Atleos, T. Rowe Price, Aurora Innovation, FedEx, Volvo, Ascendis Pharma, MoonLake Immunotherapeutics, Dyne Therapeutics, Vaxcyte, Cytokinetics, CG Oncology, Denali Therapeutics, AbbVie, Apogee Therapeutics, Bending Spoons, Mattel, Scotts Miracle-Gro, Goldman Sachs, Bank of America, JPMorgan, Citigroup, Wells Fargo, Morgan Stanley, BlackRock, ASML, TSMC, Netflix, ABB, Abbott, GE Aerospace, Intuitive Surgical, UnitedHealth, Alcoa, United Airlines, BHP, Fraport, Fastenal, Altria, Nvidia, Coca-Cola, Apple, Microsoft, Alphabet, Amazon, Broadcom, Vulcan Materials, Kansas City Southern, IBM, General Dynamics, Hershey, Tootsie Roll, Axon, Tesla, SPDR MSCI ACWI IMI (WKN: A1JJTD), iShares Edge MSCI World Momentum Factor ETF (WKN: A12ATF). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Diese Folge enthält Werbung für Smartbroker+. Depot eröffnen, 30 € ETF als Bonus sichern und aus tausenden ETFs wählen. Smartbroker+ macht Investieren einfach. Alle Informationen gibt es unter: https://get.smartbrokerplus.de/triple-aaa-podcast2/ Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

On this re-release 2 Minutes of Motivation episode of the Live Greatly podcast, Kristel Bauer shares three practical steps to take ownership of your happiness. Learn how small shifts in your mindset and daily habits can help you cultivate greater happiness, improve your well-being, and build a more fulfilling life. If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the landscape of these dynamic sectors. Starting with Ipsen's Dysport, which has made notable strides in its Phase 3 trials for migraine prevention. The trials covered both episodic and chronic conditions, marking a first in the neurotoxin market. Dysport's success positions it as a formidable competitor to AbbVie's Botox, expanding therapeutic options for individuals battling migraine disorders. This achievement showcases the potential efficacy of botulinum toxin-based therapies in neurology and pain management, offering promising new avenues for patient care. In regulatory news, Boehringer Ingelheim has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Jascayd, a small molecule PDE4B inhibitor with antifibrotic properties. This approval marks a significant milestone in the treatment of idiopathic and progressive pulmonary fibrosis. Jascayd's addition to the therapeutic arsenal offers new hope for managing this debilitating condition, emphasizing the ongoing efforts to improve patient outcomes through innovative treatments. The arena of business development sees HanChorBio partnering with InxMed to advance oncology research. By combining HCB101 with FAK inhibitors and FAP-targeted ADCs, this collaboration aims to leverage antibody and small molecule drug discovery techniques. The goal is to develop innovative cancer treatments that could redefine therapeutic approaches in oncology. Keenova Therapeutics has also reported success with Xiaflex for plantar fibromatosis. This enzyme injection therapy offers a novel approach by targeting collagen, thus providing an innovative solution for musculoskeletal conditions. Similarly, Fate Therapeutics' FT819, an off-the-shelf CAR-T therapy, has shown early promise in tackling treatment-resistant systemic sclerosis, underscoring the potential of cell therapies beyond oncology. Meanwhile, MindRank's successful Series B funding round of $52 million highlights the growing role of AI platforms in drug discovery. The funding will propel its AI-discovered oral GLP-1 obesity pill into Phase III trials, exemplifying how technology-driven solutions are gaining traction in addressing metabolic diseases like obesity. On the regulatory front, Saol Therapeutics has resubmitted SL1009 (DCA) to the FDA for pyruvate dehydrogenase complex deficiency. This submission underscores ongoing efforts to address rare metabolic disorders using small molecule therapies. Additionally, Sanofi's concessions to the EU regarding flu vaccine marketing illustrate the complexities of competitive dynamics and regulatory scrutiny within the vaccine market. However, not all developments are favorable. AstraZeneca and Ionis Pharmaceuticals faced a setback as their drug Wainua failed its Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy. This outcome highlights the challenges inherent in developing effective treatments for complex cardiovascular conditions. Meanwhile, regulatory processes remain contentious as the FDA pauses its release of complete response letters amid debates over proprietary information disclosures. In another noteworthy development, GSK has terminated its $2.2 billion collaboration with Alector after underwhelming results from Alzheimer's drug trials. This decision highlights both financial implications and strategic shifts as companies reassess risk tolerance in neurodegenerative disease research. Conversely, Roche's success with its KRAS G12C inhibitor divarasib in Phase 3 lung cancer trials underscores the promise of precision medicine. Divarasib outperformed competitors Amgen's Lumakras and Bristol Myers Squibb's Krazati, positioning Roche to potentially redefine standards of care based on genetic profiles. In a move reflecting industry trends towards collaboration and innovation risk-sharing models, AstraZeneca has partnered with Sino Biopharmaceutical on respiratory disease research. This strategic alliance represents a substantial investment aimed at expanding AstraZeneca's pipeline in respiratory therapeutics. Lastly, amidst these developments, psychedelic drugs are experiencing a renaissance in psychiatric care. Companies like Compass Pathways are pioneering clinical validation for their use in treating depression, signaling a potential paradigm shift from traditional SSRIs to newer therapeutic classes pending safety and efficacy data. Overall, these stories illustrate a dynamic interplay of scientific progress and regulatory navigation within the pharmaceutical and biotech sectors. While challenges persist—particularly in neurodegenerative disease treatment—the breakthroughs in oncology and metabolic disorder therapeutics offer hopeful prospects for improving patient care. As these industries continue evolving, integrating advanced technologies such as AI will likely play a pivotal role in shaping future therapeutic landscapes.Support the show

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that showcase the dynamic nature of this industry. In a landmark development, Vertex Pharmaceuticals has made headlines with its acquisition of Crinetics Pharmaceuticals for a staggering $10 billion. This move marks Vertex's strategic expansion into the endocrine disease sector, a significant shift from its traditional focus on cystic fibrosis. Crinetics' innovative approach to treating rare endocrine disorders will allow Vertex to address unmet needs in this area, highlighting a broader industry trend where mergers and acquisitions serve as key strategies for adapting to the evolving scientific landscape and patient demands. While Vertex makes bold moves, Kalohexis is preparing for a confidential initial public offering (IPO), focusing on treatments based on the melanocortin system for obesity and cancer cachexia. The melanocortin system is crucial in regulating energy homeostasis and inflammation, making it a promising target for therapeutic interventions. This development underscores the growing interest in peptide-based therapies and innovative scientific approaches to address complex metabolic disorders, further emphasizing the industry's shift towards tackling significant health challenges such as obesity. Clinical trials continue to be at the forefront of medical advancements. Compass Pathways has reported promising Phase III trial results for COMP360, its psilocybin-based therapy for treatment-resistant depression. These findings indicate a potential breakthrough in psychedelic therapy, offering new hope for patients who haven't benefited from existing antidepressant treatments. The exploration of psychedelics in mental health treatment represents a paradigm shift that could introduce novel therapeutic options and significantly impact patient care. Turning to regulatory news, AbbVie's Tepkinly (epcoritamab) has received European Commission approval for treating relapsed or refractory follicular lymphoma. This approval is based on robust Phase III data, underscoring the potential of bispecific antibodies as effective cancer therapies. Similarly, PharmaEssentia's Besremi (ropeginterferon alfa-2b) has obtained Health Canada approval for polycythemia vera treatment, highlighting the continued relevance of protein and interferon therapies in managing myeloproliferative neoplasms. In business development news, Novo Nordisk and Vivani Medical have partnered to develop an ultra-long-acting semaglutide implant for chronic weight management. This collaboration showcases advancements in drug delivery systems aimed at improving patient compliance and therapeutic outcomes. Meanwhile, Boehringer Ingelheim's licensing agreement with Prime Vector Technologies involves harnessing viral vectors for cancer vaccine development, emphasizing ongoing efforts to innovate within oncology. Despite these advancements, challenges persist within the industry. Notably, Bristol Myers Squibb's Krazati (adagrasib) failed its Phase III confirmatory trial in metastatic colorectal cancer with KRAS G12C mutations. This outcome highlights the complexities involved in developing targeted cancer therapies and underscores the need for continued innovation and exploration of combination treatments. The financial landscape also reflects strategic adjustments with Regeneron Pharmaceuticals reporting a $127 million charge impacting its earnings due to an in-process research and development expense. Additionally, Novartis is undergoing organizational restructuring with workforce reductions aimed at cost management within large pharmaceutical enterprises. On another front, China's recent approval of the world's first CAR-T therapy for solid tumors marks a significant leap forward from its traditional success in hematological malignancies. This development highlights the potential for CAR-T therapies to address complex challenges posed by solid tumors and could have profound implications for global cancer treatment paradigms. AstraZeneca's partnership with CSPC Pharmaceutical represents another strategic collaboration aimed at co-developing kidney disease drugs, reflecting Western pharmaceutical companies' efforts to leverage Chinese biotechnological capabilities. As companies navigate these complexities through strategic acquisitions, partnerships, and groundbreaking research, their ability to adapt will be crucial in shaping future patient care and therapeutic landscapes. The pharmaceutical and biotech industries remain at the forefront of scientific advancement, continually seeking solutions to complex medical needs while adapting to an ever-evolving global landscape.Support the show

Wed, 08 Jul 2026 03:45:00 +0000 https://jungeanleger.podigee.io/3220-borsepeople-im-podcast-s25-14-andrea-maier b7c3101dfdf6349eb8e6d654761213f3 Andrea Maier ist Country Medical Director bei Roche. Vor einem halben Jahr ist Andrea im Metropol als Sängerin aufgetreten und da hab ich sie danach angesprochen, weil ich gerade Stimmen für einen Weihnachtssong suchte. Wurde dann rasch umgesetzt und auch bei einem besonders emotionalen (Abschieds)Lied hat mir Andrea geholfen. Nun gibt es einen Börsepeople-Podcast mit der Pharma-Topanagerin und Ärztin, wir sprechen u.a. über Aufgaben bei AbbVie, Themis, GSK und vor allem Roche, aber auch über Sport, den Kilimandscharo, Nepal bzw, den Life Science Standort Österreich. Und über einen Hut. https://www.roche.at Songs mit Andrea: http://www.audio-cd.at/music Börsepeople Werner Lanthaler: https://audio-cd.at/page/podcast/7101 About: Die Serie Börsepeople des Podcasters Christian Drastil, der im Q4/24 in Frankfurt als "Finfluencer & Finanznetworker #1 Austria" ausgezeichnet wurde, findet im Rahmen von http://www.audio-cd.at und dem Podcast "Audio-CD.at Indie Podcasts" statt. Es handelt sich dabei um typische Personality- und Werdegang-Gespräche. Die Anniversary Season 25 wird nach davor 24 Seasons mit fixen Presentern und insgesamt 574 Folgen (seit 2022 jeden Montag, Mittwoch und Freitag) nun für eine Freestyle-Phase ohne fixe Sendetermine sorgen, die bis Ende Sommer dauert. Als Nebeneffekt soll die Logistik rund um Drastils Fanboy-Buch, vgl. http://www.christian-drastil.com , erleichtert werden. Welcher der meistgehörte Börsepeople Podcast ist, sieht man unter http://www.audio-cd.at/people. Der Zwischenstand des laufenden Rankings ist tagesaktuell um 12 Uhr aktualisiert. Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/spotify , http://www.audio-cd.at/apple . Du möchtest deine Werbung in diesem und vielen anderen Podcasts schalten? Kein Problem!Für deinen Zugang zu zielgerichteter Podcast-Werbung, klicke hier.Audiomarktplatz.de - Geschichten, die bleiben - überall und jederzeit! 3220 full no Christian Drastil Comm. (Agentur für Investor Relations und Podcasts) 1991

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

A judge dismissed Edgewater residents' lawsuit to overturn Broadway's rezoning. Crain's commercial real reporter Rachel Herzog talks with host Amy Guth about what's next for the neighborhood. Plus: Developer withdraws rezoning request for controversial Hoffman Estates data center, office building near Fulton Market trades at a major discount, Northwestern plans $275 million facility do-over in Orland Park amid cancer care race and AbbVie faces federal probe over drug trials in China. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Relebogile Mabotja speaks to Rakesh Harribhai the Founder of Parkinson’s ZA and Dr. Nombini Habangana a Medical Affairs Director at AbbVie unpacking the rise of Parkinsons Disease in South Africa and the causes of late diagnosis and how to detect early signs and symptoms. Through multidisciplinary interventions the disease can be manage effectively and the value of community in the management of the disease. 702 Afternoons with Relebogile Mabotja is broadcast live on Johannesburg based talk radio station 702 every weekday afternoon. Relebogile brings a lighter touch to some of the issues of the day as well as a mix of lifestyle topics and a peak into the worlds of entertainment and leisure. Thank you for listening to a 702 Afternoons with Relebogile Mabotja podcast. Listen live on Primedia+ weekdays from 13:00 to 15:00 (SA Time) to Afternoons with Relebogile Mabotja broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/2qKsEfu or find all the catch-up podcasts here https://buff.ly/DTykncj Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

In this Live Greatly 2 Minutes of Motivation podcast episode, Kristel Bauer shares 3 practical strategies to help you navigate high-pressure situations with greater confidence and resilience. Learn how to manage your attention when nerves, fear, and self-doubt arise so you can perform at your best. Tune in now! If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

Greg Doggett, Counsel, Powers Pyles Sutter & Verville PC, and Felicity Homsted, CEO, FQHC 340B Compliance, discuss the current legal and regulatory landscape of the 340B program. They cover the intersection of 340B with the Inflation Reduction Act, concerns about the Rebate Model, pharmaceutical manufacturer restrictions and data requirements for covered entities, AbbVie's patient definition lawsuit, state reporting requirements, and potential Congressional action.Watch this episode: https://www.youtube.com/watch?v=KsnP7hLbvekEssential Legal Updates, Now in AudioAHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.Stay At the Forefront of Health Legal EducationLearn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/. 

How Targeted Therapies Are Reshaping Treatment for Platinum-Resistant Ovarian Cancer Platinum-resistant ovarian cancer remains one of the most challenging settings in oncology, with limited treatment options and historically poor outcomes for many patients. On this episode of Unscripted, the AMCP Podcast, guest host Abby Kim, PharmD, BCOP, Senior Director of Clinical Strategy and Oncology Specialty Solutions at Prime Therapeutics, sits down with Kathleen Moore, MD, Deputy Director of the Fred & Pamela Buffett Cancer Center and Professor of Obstetrics and Gynecology at Nebraska Medicine, to discuss the evolving treatment landscape for recurrent ovarian cancer and the growing role of biomarker-driven care. Dr. Moore explores the history and challenges of treating platinum-resistant disease, reviews the clinical evidence behind ELAHERE®, examines the importance of folate receptor alpha testing, and shares insights on treatment sequencing, patient-reported outcomes, safety and tolerability considerations, and emerging therapies that may further expand options for patients and inform decision-making across managed care. Sponsored by Abbvie, Inc. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic shifts reshaping the industry landscape. To begin, the U.S. Food and Drug Administration has taken a noteworthy step by selecting key industry players, including Eli Lilly, Regeneron, Fujifilm, and Kriya Therapeutics, for its PreCheck pilot program. This initiative is designed to enhance U.S. drug manufacturing capabilities, emphasizing the importance of robust domestic production. By reducing dependency on international supply chains, the program aims to expedite the delivery of critical therapies, highlighting a strategic move towards self-reliance in pharmaceutical manufacturing. In oncology news, Beone's Brukinsa (zanubrutinib), a small molecule BTK inhibitor, has demonstrated a remarkable 43% reduction in risk of progression for patients with first-line mantle cell lymphoma in its Phase 3 trial. This breakthrough offers a promising chemotherapy-free option for non-Hodgkin lymphoma treatment, marking significant progress in targeted cancer therapies that could improve patient outcomes in previously underserved areas. Meanwhile, Boulevard Bio and Metis TechBio have sealed a substantial licensing agreement valued at $1.6 billion for MTS-128, a trispecific T-cell engager aimed at autoimmune diseases. This collaboration reflects a broader industry trend towards leveraging advanced AI and machine learning technologies to enhance the development of precision medicine and personalized therapies. Such partnerships indicate a shift towards more innovative approaches to tackling complex disease mechanisms and illustrate burgeoning interest in multispecific biologics within immunotherapy domains—offering new avenues for targeting multiple disease pathways simultaneously. On the regulatory front, Sanofi is advancing efforts to expand the U.S. label for Nexviazyme (avalglucosidase alfa) following successful Phase 3 trials for infantile-onset Pompe disease. As an enzyme replacement therapy targeting GAA enzyme deficiency, Nexviazyme could address a critical gap in treatment options for this debilitating genetic disorder, underlining the importance of regulatory pathways in facilitating access to life-saving therapies. Financially, Beeline Medicines has garnered $126.3 million in Series A extension funding to propel its autoimmune programs originally sourced from Bristol Myers Squibb. Similarly, SmartBax has raised €6.3 million to advance its lead antibiotic program targeting multi-drug resistant infections. These investments underscore an unwavering focus on addressing unmet medical needs through innovative therapeutic solutions. Regulatory challenges persist as well; Unicycive Therapeutics faced FDA rejection due to third-party manufacturing deficiencies surrounding oxylanthanum carbonate. This setback emphasizes the critical importance of maintaining rigorous quality standards throughout drug production processes to secure regulatory approvals and ensure patient safety. Globally, China has achieved a milestone with the approval of the world's first CAR-T therapy for solid tumors—a significant leap forward given the historical challenges of applying CAR-T technology beyond hematological malignancies. This approval could transform cancer treatment paradigms globally and prompt similar regulatory advancements in other regions. In other developments, Abbvie and Genmab's combination therapy involving Epkinly has shown promise in diffuse large B-cell lymphoma (DLBCL) trials following prior challenges with monotherapy approaches. This success story highlights the potential of combination therapies in enhancing outcomes for patients battling complex cancers like DLBCL. From a corporate perspective, Klick Health's acquisition of Oxford Pharmagenesis marks its third purchase in 18 months, expanding its global footprint and scientific capabilities—a testament to ongoing consolidation trends aimed at augmenting expertise and strategic growth within the sector. These developments collectively paint a picture of an industry dynamically evolving amidst scientific breakthroughs and regulatory recalibrations. As companies navigate this transformative landscape, their ability to adapt and innovate remains paramount for sustaining growth and addressing global healthcare challenges effectively. Stakeholders must remain agile to seize opportunities while mitigating inherent risks in this high-stakes environment that increasingly prioritizes patient-centric innovations.Support the show

On this podcast episode, we spotlight our IPhO Annual Meeting Premier Sponsor, the USC Mann Pharmaceutical Industry Fellowship Program. We are joined by Michael Lim, USC Fellowship Director; along with former fellows Keya Patel, who transitioned from Gilead's Global Medical Affairs HIV Prevention Fellowship to a Global Medical Affairs strategy role in HIV Treatment; and Trey Graham, who transitioned from AbbVie's Medical Affairs Evidence Planning and Execution Fellowship to a Dermatology Medical Science Liaison role. Michael, Keya, and Trey discuss the USC fellowship experience, highlighting the program's supportive structure, professional development opportunities, and resources that help fellows successfully transition into full-time roles. They also share practical advice on taking initiative, setting expectations with preceptors, building meaningful professional relationships, and maximizing the fellowship experience.  Whether you're just starting pharmacy school, finishing your fellowship, or preparing to launch your career, this episode is packed with insights you won't want to miss!

Julián Coca, asesor de inversiones de Alterarea, comparte su análisis cobre qué esperar de los resultados de Nike, sobre Merck y AbbVie y Sandisk.

With scores of pending lawsuits involving drugmaker and covered entity challenges of how federal and state governments regulate 340B, the courts have become an important arena in the national 340B debate. 340B Health's Vice President of Legal and Policy Amanda Nagrotsky unpacks some of the cases and what they might mean for 340B's future.Courts Wrestle With Issues of Federal and State AuthorityDrug companies have filed about 80 lawsuits challenging state contract pharmacy protection laws. Nagrotsky says drugmakers are arguing these state laws conflict with federal oversight, but most courts so far have ruled that contract pharmacy protection laws fall within a state's ability to regulate drug distribution and delivery. A recent decision from a federal judge in Mississippi was a major win for covered entities because it completely dismissed a drugmaker's challenge to the state's law rather than just ruling on whether to pause enforcement of the law. AbbVie Challenges 340B Patient DefinitionDrugmaker AbbVie is suing the Health Resources & Services Administration (HRSA) directly, arguing that the definition of whom the agency considers a 340B-eligible patient is too broad. AbbVie's own, narrower patient definition would require drug companies to discount far fewer drugs and thus would limit hospital access to 340B savings significantly. The government is asking the court to dismiss the lawsuit on procedural grounds, and 340B Health along with two member hospitals are asking the court to allow them to intervene as defendants and provide additional arguments for why it should throw out the case.Uncertainty Remains Despite GPO, Child Site RulingsFederal district court decisions found that HRSA failed to explain why it adopted a 2013 policy barring certain 340B hospitals' use of group purchasing organizations (GPOs) to make initial purchases for their virtual inventory systems and a 1994 policy establishing registration prerequisites for new 340B hospital outpatient facilities. Although the government opted against appealing the ruling striking down the GPO policy, the underlying prohibition remains in effect, leaving hospitals in limbo as to how HRSA will interpret the law. The government has appealed the child site ruling, and a final decision on that case will have a major impact on how quickly hospitals can use 340B drugs at new child sites.

In this re-release Live Greatly: 2 Minutes of Motivation episode, Kristel Bauer shares two powerful strategies to help you become a more effective communicator. Whether you're leading a team, navigating challenging conversations, or looking to strengthen your personal and professional relationships, these practical insights can help you communicate with greater impact and connection. Tune in now! If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

On this week's episode, Josh Schimmer, Eric Schmidt, Tess Cameron, and Sam Fazeli open by noting the XBI's continued rise, debating whether biotech is getting ahead of itself. The co-hosts call this a “new era” in which biotech can be profitable rather than sold off to pharma. The conversation shifts to deals, with AbbVie's $10.9 billion acquisition of Apogee, which raised questions about China-sourced drugs given their volume, pace of innovation, and cheaper price. The group also covers Boundless Bio and Serapha's merger, alongside a $230M private raise. Ollin Bio -- whose pipeline is built entirely on Chinese assets -- raised $330M Series B to advance Phase 3 trials of a bispecific antibody for diabetic macular edema and wet AMD, which led to a debate on the COINS Act and the distinction between physical and innovation supply chains. The group then overviews potential FDA Commissioner candidates, with BIO CEO John Crowley and physician Heidi Overton as front-runners alongside acting leader Kyle Diamantas. In company news, CVS Caremark deferred adding $SPRY's epinephrine nasal spray Neffy to its formulary, pushing the review to January 2027. The episode concludes with data updates from Moonlake in HS, Merck's ulcerative colitis drug, Definium's Phase 3 LSD data in MDD, and Absci's Lilly-backed prolactin antibody raise. *This episode aired on June 26, 2026.

This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Lorenz Raeber Want to watch that extended interview on https://esc365.escardio.org/event/2558?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2558   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über die Umsatz-Vervierfachung von Micron, schwere Vorwürfe gegen Alibaba und die Rettung einer Meme-Aktie. Außerdem geht es um Nvidia, United Airlines, Expedia, Booking Holdings, Wendy's, Alphabet, Verizon, Qualcomm, Cerebras Systems, Rheinmetall, TKMS, JPMorgan Chase, ExxonMobil, Johnson & Johnson, AbbVie, UnitedHealth Group, Chevron, HSBC, Applied Materials, Apple, Cisco Systems, Samsung Electro-Mechanics, Samsung Electronics, Vanguard FTSE All-World High Dividend Yield (WKN: A2PLTB), FTSE All-World (WKN: A2PKXG), iShares MSCI World Quality Dividend Advanced (WKN: A2P3WJ), iShares Core MSCI World (WKN: A0RPWH), iShares Euro Stoxx Select Dividend 30 (WKN: A2QP38), Fidelity Emerging Markets Quality Income (WKN: A2DWQW) und WisdomTree Megatrends ETF (WKN: A3EYCN). Und mit dem Code „AAAFRIENDS“ spart ihr jetzt 50 Prozent auf Eure Tickets beim Finance Summit am 2. Oktober – aber nur unter diesem Link: https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3f3501d84859 Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into the latest scientific breakthroughs, regulatory advancements, and strategic industry movements that are shaping the landscape of healthcare innovation. Kicking off with significant strides in drug approvals, Carsgen Therapeutics has marked a major milestone with the approval of satricabtagene autoleucel by China's National Medical Products Administration. This cell therapy is designed to target Claudin18.2-positive advanced gastric and gastroesophageal junction adenocarcinoma, a notoriously tough solid tumor. The approval follows successful Phase 2 trials, underscoring progress in targeted cancer therapies—a field particularly crucial for gastric cancers due to their heterogeneous nature. Meanwhile, Sanofi's Cenrifki (tolebrutinib) has gained approval in the EU for secondary progressive multiple sclerosis treatment. As a small molecule BTK inhibitor, it demonstrated efficacy during Phase 3 trials, providing a new avenue for managing progressive neurological disorders. This approval marks an important addition to therapeutic options for conditions with historically limited treatments. In parallel developments reflecting the shift towards precision medicine, Pierre Fabre's Braftovi (encorafenib) received European Commission approval as a first-line treatment for BRAF V600E-mutant metastatic colorectal cancer. Similarly, Gilead Sciences' Trodelvy (sacituzumab govitecan) has been approved as a first-line treatment for unresectable or metastatic triple-negative breast cancer in the EU, highlighting the expanding role of antibody-drug conjugates in oncology. AbbVie's Skyrizi (risankizumab) also gained European endorsement for pediatric use in moderate to severe plaque psoriasis. As an IL-23 inhibitor monoclonal antibody, Skyrizi exemplifies the growing trend of biologics targeting autoimmune conditions with high specificity and efficacy. On the regulatory front, the U.S. Department of Health and Human Services and FDA have launched an unprecedented initiative to reduce clinical trial timelines. This reform aims at reinforcing U.S. leadership in drug development by addressing operational efficiencies crucial for accelerating new therapies' availability, especially in oncology and rare diseases. Efforts to expedite Phase 1 clinical trials by up to 12 months are underway by federal health agencies aiming to enhance U.S. competitiveness against China's burgeoning clinical development capabilities. Economic forecasts are predicting that Eli Lilly's tirzepatide will lead a surge in global drug sales driven by obesity treatments, potentially reaching $2 trillion by 2032. As a GLP-1 receptor agonist, tirzepatide's success underscores the growing emphasis on metabolic disorders as major therapeutic targets due to their widespread prevalence and impact on public health. Strategic partnerships continue to shape the industry landscape. Merck KGaA and Versant Ventures have launched Saturnus Bio with a $50 million investment aimed at advancing therapies for rare genetic heart diseases. In another instance of strategic collaboration, Bayer is working with Iambic Therapeutics to leverage AI-driven discovery for challenging small-molecule targets, reflecting an increasing reliance on artificial intelligence to overcome traditional drug discovery hurdles. In clinical trials, Corxel Pharmaceuticals' CX11 met primary endpoints in Phase 2 studies for obesity, showcasing promising weight loss results with an oral GLP-1 small molecule. This advancement could potentially offer more accessible treatment options compared to injectable formulations. However, challenges persist as seen with Sangamo's bankruptcy filing amidst acquisition interest from Eli Lilly and Astellas, highlighting financial vulnerabilities even among pioneering gene therapy entities. Additionally, setbacks in pivotal trials like Exelixis' Zanzalintinib missing its colorectal cancer endpoint illustrate the high-risk nature of oncology drug development despite anticipated FDA approval. Across the sector, Pfizer's acquisition of Seagen faced hurdles when their antibody-drug conjugate sigvotatug vedotin failed in a Phase 3 trial for non-small cell lung cancer. This setback highlights risks inherent in biopharmaceutical investments and innovations. As these developments unfold, they reflect a dynamic industry driven by scientific innovation, strategic collaborations, and regulatory shifts aimed at enhancing patient care through more effective and tailored therapies. The increasing integration of technology such as AI in drug discovery further underscores the evolving landscape of pharmaceutical R&D toward precision medicine and operational efficiency. Today's insights not only signify groundbreaking scientific advances but also illustrate how companies adapt to regulatory environments and market opportunities—all critical elements that will shape the future direction of global healthcare delivery. Stay tuned for more updates as we continue exploring these transformative changes across the pharmaceutical and biotech industries on Pharma Daily.Support the show

This year has been partly defined by a return to M&A. In the first quarter of 2026, biopharma spent nearly $47 billion in acquisitions across 19 deals, and this week, AbbVie notched another one for the second quarter, scooping up Apogee Therapeutics and its IL-23 blocker for atopic dermatitis for around $10.9 billion. The deal follows GSK's $10.6 billion Nuvalent Bio acquisition earlier this month. These deals come as several big pharmas face patent cliffs. Sanofi, for example, will lose patent protection on Dupixent in 2031. New CEO Belén Garijo made a major play to build out Sanofi's pipeline this week, announcing that Xaira veteran Paulo Fontoura will step in as R&D chief as Houman Ashrafian exits.  Another key trend over the past 18 months has been regulatory uncertainty. This trend continues, with both uniQure and REGENXBIO announcing FDA reversals for their gene therapies for Huntington's disease and Hunter syndrome, respectively. Both companies will submit for approval of their products—a first submission for uniQure and a resubmission for REGENXBIO—in the third quarter, after the agency, under the leadership of acting commissioner Kyle Diamantas, deemed their current data sufficient. Also at the FDA, a policy memo on the agency's consideration of Sanofi's Commissioner's Priority Review Voucher for type 1 diabetes drug Tzield threw more fire on the CNPV program, which has already been mired in controversy. And the agency debuted an investigational new drug pilot program that would leverage collaborations with U.S. research institutions to reduce early trial timelines by as much as 12 months. For a special treat, we heard from BioSpace Managing Editor Jef Akst and Senior Editor Annalee Armstrong who are currently in San Diego enjoying BIO 2026. And finally, on the Eli Lilly front, a new report from Evaluate projects that the company's weight loss franchise will account for nearly half of the total sales of the top 10 drugs in 2032. But Lilly isn't resting on this envisioned success: the juggernaut is one of two companies circling Sangamo's assets as the biotech files for bankruptcy.

Peter Holsten is selling a 17-building portfolio and the firm as he prepares for retirement. Crain's commercial real estate reporter Rachel Herzog discusses with host Amy Guth. Plus: Pritzker wants legislators to take up data centers in the fall, AbbVie to buy immunology drugmaker Apogee for close to $11 billion, Gracias' Valor to raise $2.5 billion fund amid SpaceX backing and Chicago Fed's Goolsbee says too-high inflation is "going the wrong way." Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the takeout and the assets AbbVie gains.The analysts then discuss moves by FDA to reverse controversial setbacks that occurred under the agency's former leadership and assess Acting CDER Director Michael Davis' memo outlining how his predecessor repeatedly overruled career staff to quash a drug approval. The analysts also discuss continuing signs of political involvement at FDA.Finally, they discuss China NMPA's first-ever approval of a CAR T for solid tumors, satricabtagene autoleucel (satri-cel) from Carsgen.View full story: https://www.biocentury.com/article/659864#BiotechMA #Immunology #FDA #CART #ChinaBiotech00:59 - AbbVie Buys Apogee05:20 - uniQure U-turn09:02 - FDA Reversals12:32 - Tzield Memo20:53 - Solid Tumor CAR T ApprovalTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Mit eigenem KI-Chatbot, der dir alle Fragen rund ums Investieren beantwortet. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Alan Greenspan ist verstorben. Alphabet verliert KI-Star, investiert in A24. AbbVie kauft Apogee, CRH schnappt sich Arcosa. Getty verdoppelt sich durch OpenAI. Deutschland kauft bei KNDS. SpaceX vermietet und verkauft. Danone will Protein. Carl Zeiss kauft sich selbst. Secunet (WKN: 727650) ist der IT-Sicherheitsdienstleister der Bundesrepublik. Auftragseingang fast verdoppelt. Rüstung, Quantenverschlüsselung und eGates treiben. Aber zahlt sich das auch in der Marge aus? Li Ning (WKN: A0M0Z9) holt Steph Curry für 400 Mio. $. Chinas Nike mit nur 3% Wachstum, aber einem KGV unter 10 und 4% Dividende. Katalysator oder Value-Trap? Diesen Podcast vom 23.06.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic shifts that are shaping the future of healthcare. In a remarkable development from China, Carsgen has achieved approval for the world's first CAR-T therapy targeting solid tumors. This therapy focuses on Claudin18.2, marking an unprecedented expansion of CAR-T applications beyond hematologic malignancies. The significance of this breakthrough cannot be overstated, as it opens new avenues for treating cancers resistant to traditional therapies, offering hope to patients worldwide. Meanwhile, in regulatory news, the U.S. is closely examining Germany's proposed drug spending reforms due to concerns over "persistent underpayment" for new medications. This scrutiny highlights the complexities of international pharmaceutical pricing and could have profound implications for drug accessibility and pricing strategies across Europe. Sanofi is undergoing transformative changes under CEO Belen Garijo's leadership. The departure of R&D chief Houman Ashrafian and the appointment of Paulo Fontoura, known for his work at Roche, signal a strategic pivot to rejuvenate Sanofi's research and development pipeline. This move aims to address challenges within Sanofi's pipeline and inject new energy into its R&D initiatives. Reflecting broader industry trends, Eli Lilly is reevaluating its marketing strategies amid increasing emphasis on pharmaceuticals in mainstream health discussions. This introspection aligns with efforts across big pharma to enhance corporate image alongside product portfolios. The Federal Trade Commission recently mandated that Aurobindo divest four drugs as part of its $250 million acquisition of Lannett, addressing antitrust concerns and ensuring competitive balance in the generics market. Pfizer has made headlines with a rapid $10 billion oncology deal with Innovent Biologics. This collaboration underscores an industry trend towards swift, large-scale partnerships aimed at expanding global pharmaceutical ambitions. The deal's finalization in under five months illustrates the increasing pace at which such collaborations are being forged. Moderna continues to expand its mRNA capabilities beyond COVID-19 with unanimous FDA advisory committee support for its influenza vaccine candidate. This advancement signifies Moderna's strategic entry into broader vaccine markets, leveraging its mRNA platform to potentially transform vaccine development for seasonal influenza. AbbVie's acquisition of Apogee Therapeutics for $10.9 billion marks a competitive maneuver in the dermatology space. With a promising late-phase eczema drug candidate, AbbVie positions itself against market leaders like Eli Lilly, Regeneron, and Sanofi. Definium Therapeutics has announced promising phase 3 data for its novel LSD-based treatment for depression. This development has the potential to revolutionize mental health treatment paradigms by demonstrating unprecedented efficacy in psychedelic therapeutics. In an innovative stride forward, Insilico Medicine's collaboration with SK Biopharm on an AI-driven drug discovery initiative highlights the growing reliance on artificial intelligence to accelerate drug development pipelines. Targeting neuroimmune disorders, this partnership could be valued at over $2.5 billion, exemplifying AI's transformative potential in pharmaceutical innovation. These developments collectively highlight an industry characterized by rapid scientific advancements and strategic realignments. By expanding CAR-T therapies to solid tumors and integrating AI-driven drug discovery approaches, alongside significant regulatory updates and strategic collaborations, the pharmaceutical and biotech sectors are poised for continued evolution in patient care and drug development methodologies. As we continue to witness these transformative changes across pharmaceuticals and biotechnology, it remains crucial for stakeholders to adapt swiftly and collaborate effectively. The integration of novel technologies such as mRNA platforms, gene editing advancements, and AI-driven research will undoubtedly shape future healthcare outcomes and redefine traditional approaches to medicine. Thank you for tuning into Pharma Daily. We hope you found today's insights valuable as we navigate these dynamic shifts within the pharmaceutical and biotech landscapes together. Stay informed and join us next time as we continue to explore the cutting-edge developments driving healthcare innovation forward.Support the show

Plus: Apogee shares shoot higher as the pharmaceutical giant AbbVie agrees to buy the biotech company for about $10.9 billion. Shares of Intel and Micron climb amid memory-chip shortage. Alexis Green hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla, David Faber and Sara Eisen led off the show with market reaction to positive comments by Vice President Vance about the U.S.-Iran negotiations. AI in the spotlight: Chevron announced it signed a 20-year agreement with Microsoft to provide power for the tech giant's massive West Texas data center project. The anchors remembered the influential former Fed chairman Alan Greenspan, who died Monday at the age of 100. Also in focus: President Trump's comments on Anthropic and national security, Microsoft CEO Satya Nadella's message for companies leading the AI boom, SpaceX shares on track for a three-day losing streak, AbbVie agrees to buy immunology drugmaker Apogee Therapeutics for $10.9 billion in cash. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Whiplash hits geopolitical headwinds as a back-and-forth in U.S. and Iran talks fluctuate the price action in futures. Tom White explains why investors should take headlines out of Iran "with a grain of salt" as peace talks to fully reopen the Strait of Hormuz continue. In equities, Tom talks about the price target hikes in AI semiconductor equipment makers and AbbVie's (ABBV) $10.9 billion acquisition of Apogee Therapeutics (APGE). He also touches on reports of SpaceX (SPCX) preparing a $20 billion offering. ======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

2,5% Zinsen p.a. auf ein unbegrenztes Guthaben mit bis zu fünfmal der gesetzlichen Einlagensicherung*. Auch für Kinder. Das gibt's bei Scalable Capital. Mehr Infos hier. Iran droht mit Sperrung der Straße von Hormus. Unicredit hält 40% der Commerzbank. Jio plant größten IPO Indiens. Google verliert nächstes KI-Talent an Anthropic. BaFin feuert Berenberg-Chefs. AbbVie kauft Apogee. Fujikura kann auch KI. Ryanair hält O'Leary. AT&S (WKN: 922230) baut Substrate für Chips. Auch für KI-Chips. Die Aktie ist 600% im Plus seit Jahresbeginn. Aber wie lange hält der Boom? Churchill Downs (WKN: 923011) besitzt das Kentucky Derby, die größte Pferdewett-Plattform und Hunderte Glücksspielautomaten. Marktanteil bei Pferdewetten: über 60%. KGV bei 12. Diesen Podcast vom 22.06.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. *Veränderlicher Zins auf unbegrenztes Guthaben. Konditionen sowie Guthabenverteilung auf scalable.capital/tagesgeld. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode Overview:In this episode of The World According to Boyar, Jonathan Boyar speaks with Lina Tetelbaum, a corporate partner at Wachtell Lipton, one of the world's most influential corporate law firms, where she heads the firm's shareholder engagement and activism defense practice.Lina takes us inside the world of shareholder activism — how activists choose targets, the small universe of ideas they typically push, how companies and boards respond, and why so many activist campaigns ultimately end in settlements rather than full proxy fights.We discuss the tension between the changes activists typically call for and long-term business strategy, the role of index funds and proxy advisors, how activists build positions, what really happens behind the scenes in settlement negotiations, and why even controlled companies are not completely immune from activist pressure.Lina also shares her perspective on Wachtell Lipton's history in takeover defense and activism, from the era of the poison pill to today's more complex battles between boards, activists, institutional investors, and other stakeholders.Topics discussed include: shareholder activism, proxy fights, activist settlements, board governance, index funds, ISS and Glass Lewis, activist nominees, controlled companies, capital allocation, M&A, and long-term value creation.To receive more of Boyar's research, interviews, and thoughts on investing, subscribe to our Substack at boyarresearch.substack.comAbout Lina Tetelbaum:Elina (Lina) Tetelbaum is a Corporate Partner and Head of Shareholder Engagement and Activism Defense at Wachtell, Lipton, Rosen & Katz.  Lina regularly counsels on proxy fights, takeover defense, corporate governance, crisis management and mergers and acquisitions. Lina has been named a Dealmaker of the Year by The American Lawyer, one of The Deal's Top Women in Dealmaking, a Power Player in Shareholder Activism by Financier Worldwide, a Leading Partner in Shareholder Activism by Legal500, a Law360 Rising Star for M&A, and one of the 500 Leading Dealmakers in America by Lawdragon, among other honors.Lina has advised companies in numerous industries navigating activist situations across an array of established and new activists, including Phillips 66 in its response to three years of activism from Elliott Management and first-ever contested vote by Elliott in the United States, United States Steel Corporation in its successful defense against a proxy contest by Ancora, The J.M. Smucker Co. in its response to activism by Elliott Management, Hexcel Corporation in response to activism by Vision One, Macy's, Inc. in its response to activism and unsolicited takeover proposals, Match Group in its response to activism by Elliott Management and later Anson Funds, and numerous REITs in their response to activism by Land & Buildings.  Lina has extensive expertise advising companies in response to unsolicited takeover offers, including National Instruments in its $8.2 billion acquisition by Emerson following its unsolicited offer, and Kansas City Southern in its unsolicited transaction with Canadian National Railway and $31 billion acquisition by Canadian Pacific Railway. Lina has also advised public and private companies in a wide range of industries in mergers and acquisitions, including The Free Press in its acquisition by Paramount, Allergan in its $83 billion acquisition by AbbVie, PDC Energy in its $7.6 billion acquisition by Chevron and successful proxy fight defense against Kimmeridge, Barnes Group in its $3.6 billion acquisition by Apollo Global Management, and Masonite International in its $3.9 billion sale to Owens Corning. Lina is the President of the Stuyvesant High School Alumni Association, an Advisory Board Member of the Harvard Law School Program on Corporate Governance, the John L. Weinberg Center for Corporate Governance at the University of Delaware, and the Yale Law School Center for the Study of Corporate law. She frequently lectures, presents and publishes on corporate governance and M&A at law schools and corporate governance conferences around the world. Lina received an A.B. magna cum laude in Economics from Harvard University and completed a J.D. from Yale Law School, where she served as editor-in-chief of the Yale Journal on Regulation and editor of the Yale Law Journal. After law school, Lina served as a law clerk to the Chief Judge of the U.S. Court of Appeals for the Ninth Circuit. Unlocking Investment Opportunities Since 1975At the Boyar Value Group, we've dedicated nearly five decades to the pursuit of value on behalf of our clients. Founded in 1975, our firm has earned a reputation as a trusted source for uncovering undervalued opportunities in the stock market.To find out more about the Boyar Value Group, please visit www.boyarvaluegroup.com

Host: Wilfried Mullens Guest: Stephan Baldus Want to watch that extended interview, go to: https://esc365.escardio.org/event/2560?resource=interview Want to watch that entire episode? Go to: https://esc365.escardio.org/event/2560   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Transcatheter treatment of tricuspid regurgitation Carcinoid heart disease Milestones: MADIT-II Trial Host: Wilfried Mullens Guests: Stephan Baldus, Heidi Connolly and Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2560 Want to watch that extended interview on transcatheter treatment of tricuspid regurgitation, go to: https://esc365.escardio.org/event/2560?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Heidi Connolly, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The pharmaceutical and biotech industries are undergoing significant transformations, driven by scientific advancements, regulatory changes, and strategic investments. These developments are shaping the landscape of drug development and patient care in profound ways. In recent news, Pfizer's CEO, Albert Bourla, is reconsidering investments in Germany due to proposed healthcare reforms. These reforms have sparked concerns about their potential impact on the pharmaceutical industry. This situation highlights the intricate balance between regulatory frameworks and corporate strategies, illustrating how policy changes can influence investment decisions and operational strategies within the pharma sector. The tension between regulatory environments and corporate interests is a recurring theme that continues to shape strategic directions within the industry. Meanwhile, heightened scrutiny over biotechnology operations is evident with Wuxi AppTec's inclusion on the Pentagon's blacklist under the Biosecure Act. This move reflects growing concerns about biosecurity and the necessity for stringent oversight in handling sensitive biotechnological advancements. Such actions underscore a global focus on safeguarding national security while fostering scientific innovation. Teva Pharmaceuticals is navigating restructuring efforts by laying off 250 employees at its Active Pharmaceutical Ingredients unit as it seeks a new owner. This restructuring underscores the challenges companies face in maintaining operational efficiency amid ownership transitions. These challenges are emblematic of broader industry dynamics where companies strive to adapt to changing market conditions while ensuring stability and growth. On the scientific front, Novo Nordisk's cagrisema and Eli Lilly's retatrutide are emerging as next-generation incretin therapies. Although early comparisons have been made, Novo Nordisk's chief scientific officer suggests it is premature to declare a definitive leader. This competition reflects the dynamic nature of drug development as companies strive to innovate and improve treatment options continuously. Additionally, Sonothera's successful $125 million Series B funding round for its bubble-based genetic delivery system highlights the biotech industry's momentum fueled by mergers and acquisitions (M&A) and partnerships. Such technologies promise to advance genetic therapies by enhancing delivery mechanisms, potentially transforming treatment paradigms for various genetic disorders. AbbVie's Skyrizi narrowly surpassing Johnson & Johnson's Tremfya in May drug ad spending underscores the competitive nature of pharmaceutical marketing. Despite a general slump in advertising expenditures among leading drugs, strategic marketing remains crucial for maintaining brand presence and market share. Increased M&A activity and partnerships are further bolstering the industry's growth trajectory. The resurgence of Initial Public Offerings (IPOs) and venture capital funding is fostering innovation and expansion within the sector, providing fuel for continued advancement in biotech. On the regulatory front, Johnson & Johnson's Darzalex received a new endorsement from NICE after a prior reversal. Such regulatory updates emphasize the evolving nature of drug approvals and market access strategies essential for pharmaceutical companies' success. Novartis' second deal with Orionis Biosciences worth up to $1.4 billion exemplifies strategic investments aimed at expanding research capabilities and addressing unmet medical needs through molecular glue technologies targeting challenging therapeutic areas. Conversely, Sanofi's decision to halt a Phase 3 autoimmune trial due to insufficient efficacy highlights the inherent risks in drug development pipelines. These setbacks emphasize the importance of robust clinical trial designs and adaptability in R&D strategies. Emerging insights into GLP-1 drugs like Novo Nordisk's semaglutide reveal potential antidepressant effects linked to gut microbiota modulation. These findings open new avenues for exploring psychiatric applications of metabolic drugs, although conflicting data necessitates further investigation. Overall, these developments illustrate a complex interplay of scientific innovation, regulatory dynamics, and strategic corporate actions driving the future of pharmaceuticals and biotechnology. The sector continues to navigate challenges while capitalizing on opportunities to enhance patient care through advanced therapeutic solutions. The industry's trajectory promises transformative impacts on patient care through novel therapies designed not only to treat symptoms but also address root causes via innovative science-driven solutions. As these advancements unfold, they herald a new era of targeted, effective treatments that hold promise for improving patient outcomes across diverse medical landscapes.Support the show

https://gostudiopro.com/transformAre your financial decisions driven by strategy, or by a money story you've been carrying for years?  Many dance studio owners start with a passion for changing lives, but struggle to balance purpose with profitability. In this conversation led by Katie Wilber (DSOA Operations Specialist), financial strategist Mel Abraham shares how our beliefs, habits, and behaviors around money shape the way we run our businesses and why building wealth has far more to do with mindset than math. You'll learn how to break free from limiting financial beliefs, create a healthier relationship with money, and build a studio business that supports both your mission and your life.  What You'll Learn  How childhood money stories influence business decisions  Why wealth-building is primarily about behavior and habits  The truth behind the "starving artist" mindset  How to connect profit with purpose without guilt  Why owning your value is essential for growth  The difference between making money and building wealth  How wealthy people prioritize investing differently  Strategies to avoid emotional spending and instant gratification  How money can create (or reveal) tension in relationships  Why defining your version of "enough" is critical for long-term success  How to align your financial decisions with your values and life goals  Mel Abraham is a CPA, entrepreneur, financial strategist, keynote speaker, and author of Building Your Money Machine. He helps entrepreneurs and leaders remove financial constraints, build lasting wealth, and create systems that separate income from effort. Mel has worked with organizations including AbbVie, the IRS, NACVA, and the Financial Planning Association, and is one of the few speakers worldwide to earn the Certified Speaking Professional designation.    Explore our partners: Get ahead of next season with Limelight Teamwear. Visit limelightteamwear.com to learn more. Sign-up for a FREE 30-day Trial of Studio Pro at gostudiopro.com/transform Join our growing community of people just like you inside our free Facebook group. Click here to join!  Follow The Dance Studio Owners Association:  Instagram: @dancestudioownersassociation | TikTok: @dsoaofficial | Facebook: @dancestudioownersassociation  

Want to become a better leader? Start by leading yourself well. In this re-release 2 Minutes of Motivation Live Greatly episode, Kristel Bauer shares an often-overlooked leadership strategy: investing in your own well-being. When you prioritize your physical, mental, and emotional health, you're better equipped to show up for your team, make thoughtful decisions, and lead with intention. Small investments in yourself can have a powerful ripple effect on those around you. Interested in bringing these types of strategies to your organization? Learn more about Kristel Bauer's keynotes and workshops at livegreatly.co. If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the evolving landscape of the pharmaceutical and biotechnology industries, where scientific advancements, regulatory updates, and strategic business decisions are reshaping the future. A significant development in this dynamic arena is the strategic withdrawal by Eli Lilly and Boehringer Ingelheim from planned investments in Germany. Both companies have decided to cut at least $1 billion each from their investments, a direct response to Germany's healthcare reforms targeting reduced branded drug prices. This decision highlights how governmental policy can significantly influence pharmaceutical investment strategies, prompting companies to be more cautious in markets with strict pricing controls. Another critical area of focus is clinical trials, where ADC Therapeutics has encountered a significant challenge. The company's antibody-drug conjugate, Zynlonta, which was granted accelerated FDA approval in 2021, recently reported three times as many deaths in its study arm compared to the control group. This raises important questions about the safety profile of antibody-drug conjugates, a class of drugs celebrated for their potential in targeted cancer therapy. The situation underscores the ongoing struggle to balance efficacy with safety in innovative cancer treatments. Regulatory oversight remains a pivotal aspect of the industry. The FDA recently issued a warning letter to Medline over recurring issues with toxic bacteria in finished products, emphasizing the critical need for compliance and safety within the medical device sector. Additionally, an untitled letter was sent to QOL Medical for potentially misleading promotional communications regarding Sucraid. Such actions demonstrate the FDA's vigilance in monitoring marketing practices that could mislead healthcare providers or patients. In drug approval news, AbbVie's Qulipta and Amgen's Imdelltra have secured approvals in Europe. These milestones are part of a broader strategy by pharmaceutical companies to expand geographically and enhance product portfolios through new indications. Meanwhile, Axsome Therapeutics successfully defended its narcolepsy medication Sunosi against generic competition until 2040 by settling patent litigation with a prospective generic manufacturer. This move reflects the intense patent battles common in the industry to extend product lifecycles and maintain market exclusivity. Turning to geopolitical influences, there is heightened scrutiny on China's biotech sector following calls from U.S. lawmakers for increased oversight. The potential application of the Comprehensive Outbound Investment National Security Act to Chinese biotech investments signals escalating tensions and could significantly impact international collaborations and investments. This reflects growing concerns over intellectual property protection and biotechnological advancements within international trade dynamics. In financial developments, Parabilis Medicines is preparing for an IPO with aims to raise $476 million to fund Phase 3 trials of its desmoid tumor drug candidate. This move illustrates continued investor interest in oncology innovations despite broader economic uncertainties. On the scientific front, Autobahn Therapeutics is making strides with its thyroid hormone receptor stimulator, showing efficacy in reducing depression symptoms in bipolar disorder during Phase 2 trials. This success paves the way for pivotal trials and highlights how hormone mimics can offer new therapeutic avenues for neuropsychiatric disorders. Meanwhile, Alnylam Pharmaceuticals has entered into a groundbreaking $2 billion agreement with Inceptive Nucleics to incorporate artificial intelligence into small interfering RNA design. By leveraging AI-driven methodologies, Alnylam aims to enhance precision and efficacy in siRNA therapies, potentially speeding up drug discovery processes. Operational challenges are also evident as companies navigate complex markets like Japan, underscoring the importance of integrating regulatory and strategic planning early on to mitigate risks and ensure market feasibility. These developments paint a vivid picture of a vibrant pharmaceutical and biotech landscape where scientific innovation is rapidly advancing alongside strategic partnerships and regulatory oversight. Breakthrough technologies such as AI-driven drug design hold promise for more targeted therapies while emphasizing personalized medicine approaches. However, these advancements come with challenges like safety concerns and regulatory compliance that demand constant vigilance and adaptability from industry stakeholders. The implications for patient care are significant as these scientific breakthroughs promise new treatment avenues for complex diseases while highlighting personalized medicine approaches. As these industries continue to evolve, staying informed about scientific innovations and regulatory landscapes will be crucial for stakeholders aiming to drive future growth and improve global health outcomes. Thank you for tuning into Pharma Daily. Stay informed and stay ahead with us as we continue to bring you the latest insights from around the pharmaceutical and biotech world.Support the show

Payer & Provider Dynamics: Addressing Non-Medical Switching in Oncology for CLL/SLL On this episode guest host Ryan Haumschild, PharmD, MS, MBA, CPEL, Vice President of Pharmacy at Emory University and Emory Health Plan, Winship Cancer Institute, discusses the real-world impact of non-medical switching in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) with Timothy Mok, Manager of Clinical Utilization Intelligence at Kaiser Permanente and board-certified oncology pharmacist, focusing on the drivers behind switching, the risks of disrupting effective therapy, and how shared decision-making and dose modification can help maintain adherence and improve patient outcomes. Sponsored by Abbvie. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

In this episode of 2 Minutes of Motivation, Kristel Bauer shares 3 powerful self-leadership strategies to help you lead more intentionally and sustainably — both at work and in life. Kristel discusses: Why identifying your non-negotiables matters The importance of creating intentional reset moments throughout the day How being intentional with your relationships can positively impact leadership, culture and fulfillment This short episode is designed to help you reset, refocus and lead yourself with greater intention — especially during demanding seasons. Interested in bringing these types of strategies to your organization? Learn more about Kristel Bauer's keynotes and workshops at livegreatly.co. If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

In this re-release episode of the Live Greatly podcast, Kristel Bauer shares four powerful longevity practices that can support greater energy, resilience, well-being, and sustainable high performance in work and life. Key Takeaways: • Longevity habits that support energy and vitality • Small daily choices that can positively impact well-being • Mindset shifts that help support resilience and sustainable success Interested in bringing these types of strategies to your organization? Learn more about Kristel Bauer's keynotes and workshops at livegreatly.co. If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

Feeling stuck or uncertain about your next step? One small shift may help you start seeing new opportunities that were there all along. In this episode of 2 Minutes of Motivation, Kristel Bauer shares how getting clearer on your goals can influence what your brain pays attention to each day. Drawing on the concept of inattentional blindness, Kristel explores why clarity matters for growth, career development, confidence, and creating momentum in your life. Tune in for a quick mindset and goal-setting reset designed to help you move forward with greater intention and awareness. Key Takeaways: How your brain can filter out what it doesn't see as important How clearer goals can help you notice new opportunities Why focus and intentionality can support personal and professional growth Interested in bringing these types of strategies to your organization? Learn more about Kristel Bauer's keynotes and workshops at livegreatly.co. If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success

Bonus Episode for May 8. Financial results from pharmaceutical companies Eli Lilly, Novo Nordisk, Merck, Bristol Myers Squibb and AbbVie show strong demand continuing for weight-loss drugs and autoimmune treatments. Wall Street Journal pharma reporter Peter Loftus discusses which drugmakers have the upper hand in the race to dominate those markets.  WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Growth often begins outside of your comfort zone. In this episode of 2 Minutes of Motivation, Kristel Bauer explores how not all discomfort is negative—and how some forms of discomfort may actually be necessary for personal and professional growth. Kristel shares how she once struggled with a fear of public speaking and how learning to move through that discomfort ultimately helped shape the career she has today. Tune in to learn how reframing discomfort may help you build confidence, strengthen resilience, expand your comfort zone, and open the door to new opportunities in your work and life. Key Takeaways From This Episode: How reframing certain types of discomfort can support growth and resilience A mindset shift to help you navigate uncomfortable moments more effectively How moving through discomfort helped Kristel overcome her fear of public speaking Why growth, confidence, and new opportunities often begin outside your comfort zone Interested in bringing these types of strategies to your organization? Learn more about Kristel Bauer's keynotes and workshops at livegreatly.co. If you enjoy this episode, be sure to follow the Live Greatly podcast for more short mindset boosts and conversations with world-class leaders, authors, and experts focused on leadership, resilience, well-being, and sustainable high performance. If you're looking to support your team with sustainable high performance, resilience, and clear decision-making in high-pressure environments, Kristel brings these strategies to organizations through engaging keynote experiences. Learn more: www.livegreatly.co  Hosted by Kristel Bauer, keynote speaker, author, and performance expert. Kristel delivers high-impact keynotes on: Peak performance Burnout prevention Leadership development Workplace well-being Sustainable success